Chad M.  Robins net worth and biography

Chad Robins Biography and Net Worth

Chad Robins is the co-founder, president and CEO of Seattle-based Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine aiming to improve people's lives by learning from the wisdom of their adaptive immune systems.

Since founding Adaptive with his brother Harlan (now the company’s chief scientific officer) in 2009, Robins has led the company in developing a proprietary immune medicine platform that supports businesses ranging from life sciences research, drug discovery and clinical diagnostics. In 2019, he guided it through what was one of the most successful public offerings in biotech that year. Under his direction, Adaptive launched clonoSEQ®, the first and only FDA-authorized NGS-based test for detecting and monitoring minimal residual disease in select B-cell cancers.

Robins also launched the company into the flourishing health technology space, establishing a key partnership with Microsoft to create an AI engine capable of detecting certain diseases from a blood sample. This has fueled a pipeline of diagnostic tests for autoimmune disorders, cancer and infectious disease. Recently, Adaptive released T-Detect™ COVID, the first clinical T-cell based test for patients to affirm a prior infection of COVID-19. Additionally, the company is working to uncover potent neutralizing antibodies for the prevention and treatment of COVID-19.

Robins has received consistent recognition for innovation and excellence. In both 2019 and 2020, he was featured on the Puget Sound Business Journal’s Power 100 list, and he has been honored as a Most Intriguing Entrepreneur by Goldman Sachs every year since 2015. He was named the 2016 Ernst & Young Entrepreneur of the Year for the Pacific Northwest region. In 2012, he was recognized as a 40 Under 40 Seattle Leaders honoree.

Adaptive received Seattle Business Magazine’s Leaders in Health Care 2020 – Achievement in Medical Technology award, in addition to being recognized on Deloitte Technology’s Fast 500 list each year since 2016. In addition, under Robins’ leadership, the company has routinely been ranked as one of the Puget Sound Business Journal’s Best Places to Work.

As an active participant in the biotech and health policy spaces, Robins serves on the board of Life Science Washington and on the steering committee of the Coalition for 21st Century Medicine. He also serves on the boards of Aortica Corporation, AdvaMedDx, AltPep and HeadLight. Previously, he served as board director for the American Heart Association and American Stroke Association.

Before Adaptive, Robins held executive-level positions in medical technology, real estate and investment companies, including with Pulte Homes, Connaught Real Estate Finance and HealthAxis.com. He started his career in banking working for companies such as Wasserstein Perella and Bank of America.

Robins holds a B.S. in entrepreneurial studies from Cornell University, and he earned his M.B.A. from The University of Pennsylvania’s Wharton School of Business. 

What is Chad M. Robins' net worth?

The estimated net worth of Chad M. Robins is at least $8.27 million as of March 5th, 2024. Mr. Robins owns 2,576,701 shares of Adaptive Biotechnologies stock worth more than $8,271,210 as of March 29th. This net worth estimate does not reflect any other assets that Mr. Robins may own. Additionally, Mr. Robins receives a salary of $1,190,000.00 as CEO at Adaptive Biotechnologies. Learn More about Chad M. Robins' net worth.

How old is Chad M. Robins?

Mr. Robins is currently 50 years old. There are 3 older executives and no younger executives at Adaptive Biotechnologies. Learn More on Chad M. Robins' age.

What is Chad M. Robins' salary?

As the CEO of Adaptive Biotechnologies Co., Mr. Robins earns $1,190,000.00 per year. Learn More on Chad M. Robins' salary.

How do I contact Chad M. Robins?

The corporate mailing address for Mr. Robins and other Adaptive Biotechnologies executives is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. Adaptive Biotechnologies can also be reached via phone at (206) 659-0067 and via email at [email protected]. Learn More on Chad M. Robins' contact information.

Has Chad M. Robins been buying or selling shares of Adaptive Biotechnologies?

During the last quarter, Chad M. Robins has sold $166,948.39 in Adaptive Biotechnologies stock. Most recently, Chad M. Robins sold 48,673 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a transaction totalling $166,948.39. Following the completion of the sale, the chief executive officer now directly owns 2,576,701 shares of the company's stock, valued at $8,838,084.43. Learn More on Chad M. Robins' trading history.

Who are Adaptive Biotechnologies' active insiders?

Adaptive Biotechnologies' insider roster includes R. Adams (COO), Lance Baldo (Insider), Sharon Benzeno (Insider), Chad Cohen (CFO), Egon Durban (Director), David Goel (Director), Michelle Griffin (Director), Francis Lo (Insider), Jyoti Palaniappan (SVP), Chad Robins (CEO), Chad Robins (CEO), Harlan Robins (Insider), Julie Rubinstein (President), and Stacy Taylor (SVP). Learn More on Adaptive Biotechnologies' active insiders.

Are insiders buying or selling shares of Adaptive Biotechnologies?

During the last twelve months, insiders at the sold shares 11 times. They sold a total of 373,996 shares worth more than $2,442,187.64. The most recent insider tranaction occured on March, 5th when insider Kyle Piskel sold 7,727 shares worth more than $26,503.61. Insiders at Adaptive Biotechnologies own 5.2% of the company. Learn More about insider trades at Adaptive Biotechnologies.

Information on this page was last updated on 3/5/2024.

Chad M. Robins Insider Trading History at Adaptive Biotechnologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2024Sell48,673$3.43$166,948.392,576,701View SEC Filing Icon  
3/9/2022Sell14,815$12.46$184,594.90View SEC Filing Icon  
3/7/2022Sell4,424$12.01$53,132.24View SEC Filing Icon  
9/10/2021Sell5,000$38.38$191,900.001,705,218View SEC Filing Icon  
9/8/2021Sell13,746$38.45$528,533.70View SEC Filing Icon  
7/12/2021Sell1,501$38.24$57,398.241,716,960View SEC Filing Icon  
6/17/2021Sell5,255$39.53$207,730.151,729,361View SEC Filing Icon  
6/15/2021Sell20,000$38.27$765,400.001,729,361View SEC Filing Icon  
4/8/2021Sell5,000$42.45$212,250.001,761,861View SEC Filing Icon  
4/6/2021Sell5,000$42.18$210,900.001,761,861View SEC Filing Icon  
3/19/2021Sell5,000$41.97$209,850.001,776,560View SEC Filing Icon  
3/17/2021Sell5,000$44.16$220,800.001,776,560View SEC Filing Icon  
2/10/2021Sell10,000$62.76$627,600.001,732,466View SEC Filing Icon  
2/8/2021Sell10,000$61.61$616,100.001,732,466View SEC Filing Icon  
1/28/2021Sell10,000$56.91$569,100.001,765,930View SEC Filing Icon  
1/26/2021Sell10,000$63.53$635,300.001,765,930View SEC Filing Icon  
1/19/2021Sell8,400$70.43$591,612.001,769,880View SEC Filing Icon  
12/29/2020Sell16,790$59.28$995,311.201,794,430View SEC Filing Icon  
11/19/2020Sell16,680$46.57$776,787.601,794,860View SEC Filing Icon  
11/17/2020Sell16,680$46.12$769,281.601,794,860View SEC Filing Icon  
10/8/2020Sell24,260$50.61$1,227,798.601,796,460View SEC Filing Icon  
10/6/2020Sell18,280$49.36$902,300.801,796,460View SEC Filing Icon  
10/1/2020Sell2,500$50.15$125,375.001,780,080View SEC Filing Icon  
9/29/2020Sell1,900$50.18$95,342.001,780,080View SEC Filing Icon  
9/18/2020Sell50,040$45.76$2,289,830.401,794,860View SEC Filing Icon  
9/16/2020Sell16,680$46.44$774,619.201,794,860View SEC Filing Icon  
8/12/2020Sell7,675$37.42$287,198.501,794,860View SEC Filing Icon  
8/10/2020Sell16,680$37.63$627,668.401,794,860View SEC Filing Icon  
7/30/2020Sell16,680$37.76$629,836.801,798,848View SEC Filing Icon  
6/22/2020Sell33,132$45.85$1,519,102.201,811,312View SEC Filing Icon  
6/18/2020Sell16,680$44.41$740,758.801,806,620View SEC Filing Icon  
5/20/2020Sell50,000$40.46$2,023,000.001,928,180View SEC Filing Icon  
5/7/2020Sell45,000$35.60$1,602,000.001,923,180View SEC Filing Icon  
4/15/2020Sell10,620$28.34$300,970.801,883,740View SEC Filing Icon  
4/13/2020Sell5,560$26.04$144,782.401,883,740View SEC Filing Icon  
3/20/2020Sell5,560$22.89$127,268.401,889,300View SEC Filing Icon  
2/12/2020Sell11,120$31.30$348,056.001,889,300View SEC Filing Icon  
1/29/2020Sell11,120$30.99$344,608.801,889,300View SEC Filing Icon  
1/27/2020Sell11,120$30.01$333,711.201,889,300View SEC Filing Icon  
See Full Table

Chad M. Robins Buying and Selling Activity at Adaptive Biotechnologies

This chart shows Chad M Robins's buying and selling at Adaptive Biotechnologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adaptive Biotechnologies Company Overview

Adaptive Biotechnologies logo
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $3.21
Low: $2.93
High: $3.34

50 Day Range

MA: $3.72
Low: $2.88
High: $4.37

2 Week Range

Now: $3.21
Low: $2.61
High: $9.08

Volume

2,000,092 shs

Average Volume

1,562,798 shs

Market Capitalization

$465.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27